Cargando...

Early Primary Tumor Size Reduction Is an Independent Predictor of Improved Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib

BACKGROUND: In metastatic renal cell carcinoma (mRCC) patients treated with targeted agents and their primary tumor (PT) in situ, early PT decrease in size correlates with improved overall PT response, but the effect on overall survival (OS) is unknown. OBJECTIVE: To evaluate whether early PT size r...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Eur Urol
Main Authors: Abel, E. Jason, Culp, Stephen H., Tannir, Nizar M., Tamboli, Pheroze, Matin, Surena F., Wood, Christopher G.
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4378714/
https://ncbi.nlm.nih.gov/pubmed/21784574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2011.07.008
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!